Bausch Health Companies Inc. Payments to Acquire Debt Securities, Available-for-sale
Bausch Health Companies Inc. (BHC) reported Payments to Acquire Debt Securities, Available-for-sale of $3.82 million for the 12-month period ending 2009-12-31, per its 10-K filed 2011-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2011-02-28
- Bausch Health Companies Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2009-12-31 was $0.00.
- Bausch Health Companies Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2009-09-30 was $1.06M.
- Bausch Health Companies Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2009-06-30 was $1.74M.
- Bausch Health Companies Inc. payments to acquire debt securities, available-for-sale for fiscal 2009 was $3.82M, a 39.22% decline from fiscal 2008.
- Bausch Health Companies Inc. payments to acquire debt securities, available-for-sale for fiscal 2008 was $6.29M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.06M derived: sum of 2 quarters · filed 2011-02-28 | $2.80M derived: sum of 3 quarters · filed 2011-02-28 | $3.82M 10-K · filed 2011-02-28 |
| 2009-09-30 | $1.06M 10-Q · filed 2010-11-05 | $2.80M derived: sum of 2 quarters · filed 2010-11-05 | $3.82M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $1.74M 10-Q · filed 2010-08-06 | $2.76M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $6.29M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |